RNA data of baseline and ERY974-treated tumour samples for various xenograft tumors (PC10, NCI-H446, MKN45, and MKN74).

GPC3 expression is one of the important predictive marker of ERY974. However, we found that efficacy of ERY974 is sometimes different in tumors with the similar GPC3 expression. To identify a predictive biomrker of ERY974, we compared baseline RNA expression of tumors in which ERY974 shows moderate efficacy, and/or achives the regression with similar GPC3 expression. Comparative gene expression profiling analysis of RNA-seq data for tumors of PC10 (ERY974 shows regression/GPC3 high), NCI-H446 (ERY974 shows moderate efficacy/GPC3 high), MKN74 (ERY974 shows regression/GPC3 low), and MKN45(ERY974 shows moderate efficacy/GPC3 low).